On July 21, 2014, Zacks SCR initiated coverage of MYOS Corporation (MYOS) with a 'Buy' rating and $20 price target. A link to our full 21 research report can be found here >> REPORT.
We have also written an article for Seeking-Alpha.
- MYOS Corporation is a biotherapeutics and bionutrition company focused on improving muscle health and function to combat muscle related diseases.
- We believe a solid scientific basis differentiates MYOS from other bionutrition companies.
- Rapidly increasing revenues are helping to provide the necessary capital for research initiatives targeting muscle health.
- The company just recently listed on the NASDAQ. MYOS has a clean capital structure and strong management.
- We believe MYOS would make a good investment for those looking to get into the emerging area of muscle health. We see the shares fairly valued at $20.
Please see the full article on Seeking-Alpha's website here >> ARTICLE.
Any questions, please let me know!